ArticleScientific reports2025
Amniotic fluid glycoproteins as potential ligands for macrophage galactose-type C-type lectin and their possible implications for immunoregulation during pregnancy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.Annals of hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunity during pregnancy must be precisely balanced, because the mother's body needs to effectively fight pathogens while maintaining tolerance of the semi-allogeneic fetus. Factors that participate in achieving the proper immune balance during pregnancy include glycoproteins that expose sugar residues recognized by specific lectin receptors. Several types of lectins and their ligands have been detected at the maternal-fetal interface, and changes in their expression levels have been correlated with pregnancy complications. Although the presence of potential sugar ligands for human macrophage galactose-type lectin (MGL), including LacdiNAc and (sialo)Tn antigen, has been detected in amniotic fluid, placenta and fetal tissues, the interaction between them and its possible role have not been elucidated so far. The aims of the present study were to evaluate reactivity of MGL with amniotic fluid proteins and to identify and characterize the amniotic ligands of MGL. The analysis proved the ability of MGL to interact with amniotic glycoproteins and revealed the potential protein carriers of glycans recognized by MGL, including mucins, mucin-like proteins, and uromodulin. Bioinformatics analysis assigned the identified glycoproteins as being involved in immune processes such as regulation of signaling pathways activated in the response to Toll-like receptor (TLR) agonist stimulation or modulation of antimicrobial responses. Our research suggests that MGL-mediated interactions may be involved in maintaining the delicate immune balance during pregnancy. Our results may be helpful in future implementation of modern therapies based on the glycan ligands of MGL in the context of avoiding miscarriages and preterm birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.